View Future GrowthPolyPeptide Group 過去の業績過去 基準チェック /06PolyPeptide Groupの収益は年間平均-57.6%の割合で減少していますが、 Life Sciences業界の収益は年間 増加しています。収益は年間4.4% 8.7%割合で 増加しています。主要情報-57.58%収益成長率-58.20%EPS成長率Life Sciences 業界の成長36.86%収益成長率8.71%株主資本利益率-6.22%ネット・マージン-5.44%次回の業績アップデート13 Aug 2026最近の業績更新Reported Earnings • Mar 14Full year 2025 earnings released: €0.64 loss per share (vs €0.59 loss in FY 2024)Full year 2025 results: €0.64 loss per share (further deteriorated from €0.59 loss in FY 2024). Revenue: €391.9m (up 16% from FY 2024). Net loss: €21.2m (loss widened 8.2% from FY 2024). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.お知らせ • Dec 05+ 1 more updatePolyPeptide Group AG to Report Fiscal Year 2026 Results on Mar 09, 2027PolyPeptide Group AG announced that they will report fiscal year 2026 results on Mar 09, 2027Reported Earnings • Aug 14First half 2025 earnings released: €0.80 loss per share (vs €0.35 loss in 1H 2024)First half 2025 results: €0.80 loss per share (further deteriorated from €0.35 loss in 1H 2024). Revenue: €167.1m (up 24% from 1H 2024). Net loss: €26.5m (loss widened 133% from 1H 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.Reported Earnings • Mar 14Full year 2023 earnings released: €1.56 loss per share (vs €0.23 profit in FY 2022)Full year 2023 results: €1.56 loss per share (down from €0.23 profit in FY 2022). Revenue: €324.9m (up 16% from FY 2022). Net loss: €51.4m (down €59.2m from profit in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom.お知らせ • Dec 17+ 1 more updatePolyPeptide Group AG to Report First Half, 2025 Results on Aug 12, 2025PolyPeptide Group AG announced that they will report first half, 2025 results on Aug 12, 2025Reported Earnings • Aug 19First half 2023 earnings released: €1.04 loss per share (vs €0.31 profit in 1H 2022)First half 2023 results: €1.04 loss per share (down from €0.31 profit in 1H 2022). Revenue: €131.8m (down 1.4% from 1H 2022). Net loss: €34.3m (down 434% from profit in 1H 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in the United Kingdom.すべての更新を表示Recent updatesお知らせ • 2hSamsung Biologics Co.,Ltd. (KOSE:A207940) entered into a transaction agreement to acquire PolyPeptide Group AG (SWX:PPGN) from Draupnir Holding B.V. and others for CHF 1.5 billion.Samsung Biologics Co.,Ltd. (KOSE:A207940) entered into a transaction agreement to acquire PolyPeptide Group AG (SWX:PPGN) from Draupnir Holding B.V. and others for CHF 1.5 billion on July 17, 2026. Under the terms of the agreement, Samsung Biologics agreed to make an all-cash public tender offer to acquire all publicly held registered shares of PolyPeptide for CHF 44.31 in cash per share. The Offer values PolyPeptide's equity at approximately CHF 1.46 billion. The transaction aims to provide PolyPeptide with the resources, investment capacity and strategic platform to pursue the next phase of its growth and innovation. Alongside Samsung Biologics’ global manufacturing scale and track record of operational excellence, PolyPeptide will also benefit from an aligned customer footprint. Draupnir Holding B.V. owning a stake of approximately 56.3% stake has been in support of the strategic review process and has committed to tender all of its shares into the offer. Once the offer has been successfully completed, Samsung Biologics intends to pursue a squeeze-out of any remaining minority shares and to delist PolyPeptide from the SIX Swiss Exchange. Upon completion, PolyPeptide will operate as a wholly owned subsidiary of Samsung Biologics. The transaction is subject to approval by the shareholders of PolyPeptide Group AG, minimum acceptance threshold of 66?%, applicable regulatory approvals, and other conditions. The Board of Directors of PolyPeptide Group AG formed a special committee for the transaction. The deal has been unanimously approved by the special committee of board of directors of PolyPeptide Group AG and recommends that PolyPeptide shareholders accept the tender offer. The tender offer is expected to be launched by the end of August 2026 by publication of the formal offer prospectus and will remain open for a minimum of twenty trading days on the SIX Swiss Exchange. The transaction is expected to be completed towards the end of 2026. JP Morgan Korea acted as exclusive financial advisor to Samsung Biologics Co.,Ltd. Ernst & Young, Korea acted as accountant to Samsung Biologics Co.,Ltd. O'Melveny & Myers LLP, Seoul office acted as legal advisor to Samsung Biologics Co.,Ltd. Schellenberg Wittmer acted as legal advisor to Samsung Biologics Co.,Ltd. IFBC AG acted as fairness opinion provider to PolyPeptide Group AG. Morgan Stanley & Co. International plc acted as exclusive financial advisor to PolyPeptide Group AG. Homburger AG acted as legal advisor to PolyPeptide Group AG.New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Buy Or Sell Opportunity • Mar 31Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 5.3% to CHF27.31. The fair value is estimated to be CHF22.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company became loss making.お知らせ • Mar 18PolyPeptide Group AG, Annual General Meeting, Apr 08, 2026PolyPeptide Group AG, Annual General Meeting, Apr 08, 2026, at 16:00 W. Europe Standard Time.Reported Earnings • Mar 14Full year 2025 earnings released: €0.64 loss per share (vs €0.59 loss in FY 2024)Full year 2025 results: €0.64 loss per share (further deteriorated from €0.59 loss in FY 2024). Revenue: €391.9m (up 16% from FY 2024). Net loss: €21.2m (loss widened 8.2% from FY 2024). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.Buy Or Sell Opportunity • Jan 19Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to CHF29.73. The fair value is estimated to be CHF24.51, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.7% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 18% in a year. Earnings are forecast to grow by 92% in the next year.お知らせ • Dec 05+ 1 more updatePolyPeptide Group AG to Report Fiscal Year 2026 Results on Mar 09, 2027PolyPeptide Group AG announced that they will report fiscal year 2026 results on Mar 09, 2027お知らせ • Sep 23PolyPeptide Group AG Achieves Significant Milestone in Malmo Expansion ProjectPolyPeptide Group AG announced the successful delivery and installation of pre-built modules at its Malmo, Sweden facility. This marks a key milestone in the company's modular expansion project at the site, which aims to double its solid-phase peptide synthesis (SPPS) capacity. The expansion, first announced in January 2025, is a central component of PolyPeptide's mid-term strategy to meet rising global demand for peptide production. The EUR 100 million metabolic program investment was largely funded by a large pharmaceutical partner and will create around 100 permanent new positions. It is anticipated that the expansion will be significantly faster than previous engineering projects due to the modular construction approach. Following installation, the modules will now undergo mechanical completion and automation, followed by qualification and commissioning. Key Project Highlights: Accelerated timeline: The Malmo capacity expansion is on track to be faster than previous engineering expansions due to the modular approach. Strategic partnership: The EUR 100 million investment was largely funded by a largest pharmaceutical player. Modular construction: Pre-built manufacturing modules installed with proprietary manufacturing systems, delivered and installed on-site. Operational continuity: Existing manufacturing operations remain uninterrupted. Advanced technology: Integrated engineering, automation, and process control. Quality assurance: All modules built to meet stringent pharmaceutical GMP standards. The additional capacity will primarily support one of PolyPeptide's large commercial agreements, contributing to its long-term growth initiatives and capital deployment strategy. As communicated in its mid-term outlook, the company expects over the mid-term horizon and on average, capital expenditures of 15-20% of revenue to ensure capacity beyond 2028.Reported Earnings • Aug 14First half 2025 earnings released: €0.80 loss per share (vs €0.35 loss in 1H 2024)First half 2025 results: €0.80 loss per share (further deteriorated from €0.35 loss in 1H 2024). Revenue: €167.1m (up 24% from 1H 2024). Net loss: €26.5m (loss widened 133% from 1H 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.New Risk • Aug 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Apr 11Polypeptide Group Ag Appoints Jo Lecouilliard as Independent DirectorPolyPeptide Group AG announced the appointment of Jo LeCouilliard as Independent Director.Buy Or Sell Opportunity • Apr 07Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 52% to CHF14.27. The fair value is estimated to be CHF17.84, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years. Meanwhile, the company became loss making.New Risk • Mar 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (7.8% average weekly change).Buy Or Sell Opportunity • Jan 23Now 24% overvaluedOver the last 90 days, the stock has fallen 4.9% to CHF27.25. The fair value is estimated to be CHF21.98, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 18% in a year. Earnings are forecast to grow by 95% in the next year.New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Buy Or Sell Opportunity • Dec 16Now 29% overvaluedOver the last 90 days, the stock has fallen 8.5% to CHF29.70. The fair value is estimated to be CHF23.11, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Nov 25Now 21% overvaluedOver the last 90 days, the stock has fallen 19% to CHF27.70. The fair value is estimated to be CHF22.88, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Meanwhile, the company became loss making.New Risk • Aug 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Buy Or Sell Opportunity • Apr 02Now 23% undervaluedOver the last 90 days, the stock has risen 63% to CHF28.55. The fair value is estimated to be CHF36.86, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 8.8% in a year. Earnings are forecast to grow by 77% in the next year.Reported Earnings • Mar 14Full year 2023 earnings released: €1.56 loss per share (vs €0.23 profit in FY 2022)Full year 2023 results: €1.56 loss per share (down from €0.23 profit in FY 2022). Revenue: €324.9m (up 16% from FY 2022). Net loss: €51.4m (down €59.2m from profit in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom.お知らせ • Dec 19PolyPeptide Group AG, Annual General Meeting, Apr 09, 2025PolyPeptide Group AG, Annual General Meeting, Apr 09, 2025.お知らせ • Dec 17+ 1 more updatePolyPeptide Group AG to Report First Half, 2025 Results on Aug 12, 2025PolyPeptide Group AG announced that they will report first half, 2025 results on Aug 12, 2025Reported Earnings • Aug 19First half 2023 earnings released: €1.04 loss per share (vs €0.31 profit in 1H 2022)First half 2023 results: €1.04 loss per share (down from €0.31 profit in 1H 2022). Revenue: €131.8m (down 1.4% from 1H 2022). Net loss: €34.3m (down 434% from profit in 1H 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in the United Kingdom.Board Change • Jul 26High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. Non-Executive Director Erik Schropp is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Feb 08+ 3 more updatesPolyPeptide Group AG to Report First Half, 2024 Results on Aug 13, 2024PolyPeptide Group AG announced that they will report first half, 2024 results on Aug 13, 2024収支内訳PolyPeptide Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史LSE:0AAJ 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Dec 25389-2156230 Sep 25379-2852230 Jun 25369-3549231 Mar 25353-2746131 Dec 24337-2044130 Sep 24330-2444130 Jun 24324-2943131 Mar 24322-4042131 Dec 23320-5142130 Sep 23300-4441130 Jun 23279-3740131 Mar 23280-1440131 Dec 22281841130 Sep 222812040130 Jun 222813340131 Mar 222814036131 Dec 212824732130 Sep 212774831130 Jun 212714829131 Mar 212484028131 Dec 202243128131 Dec 192032625131 Dec 18181242412質の高い収益: 0AAJは現在利益が出ていません。利益率の向上: 0AAJは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 0AAJは利益が出ておらず、過去 5 年間で損失は年間57.6%の割合で増加しています。成長の加速: 0AAJの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 0AAJは利益が出ていないため、過去 1 年間の収益成長をLife Sciences業界 ( 8.5% ) と比較することは困難です。株主資本利益率高いROE: 0AAJは現在利益が出ていないため、自己資本利益率 ( -6.22% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/20 02:21終値2026/07/20 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PolyPeptide Group AG 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Charles PitmanBarclaysEstelle BétriseyBerenbergPatrick Andrew WoodBofA Global Research6 その他のアナリストを表示
Reported Earnings • Mar 14Full year 2025 earnings released: €0.64 loss per share (vs €0.59 loss in FY 2024)Full year 2025 results: €0.64 loss per share (further deteriorated from €0.59 loss in FY 2024). Revenue: €391.9m (up 16% from FY 2024). Net loss: €21.2m (loss widened 8.2% from FY 2024). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
お知らせ • Dec 05+ 1 more updatePolyPeptide Group AG to Report Fiscal Year 2026 Results on Mar 09, 2027PolyPeptide Group AG announced that they will report fiscal year 2026 results on Mar 09, 2027
Reported Earnings • Aug 14First half 2025 earnings released: €0.80 loss per share (vs €0.35 loss in 1H 2024)First half 2025 results: €0.80 loss per share (further deteriorated from €0.35 loss in 1H 2024). Revenue: €167.1m (up 24% from 1H 2024). Net loss: €26.5m (loss widened 133% from 1H 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
Reported Earnings • Mar 14Full year 2023 earnings released: €1.56 loss per share (vs €0.23 profit in FY 2022)Full year 2023 results: €1.56 loss per share (down from €0.23 profit in FY 2022). Revenue: €324.9m (up 16% from FY 2022). Net loss: €51.4m (down €59.2m from profit in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom.
お知らせ • Dec 17+ 1 more updatePolyPeptide Group AG to Report First Half, 2025 Results on Aug 12, 2025PolyPeptide Group AG announced that they will report first half, 2025 results on Aug 12, 2025
Reported Earnings • Aug 19First half 2023 earnings released: €1.04 loss per share (vs €0.31 profit in 1H 2022)First half 2023 results: €1.04 loss per share (down from €0.31 profit in 1H 2022). Revenue: €131.8m (down 1.4% from 1H 2022). Net loss: €34.3m (down 434% from profit in 1H 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in the United Kingdom.
お知らせ • 2hSamsung Biologics Co.,Ltd. (KOSE:A207940) entered into a transaction agreement to acquire PolyPeptide Group AG (SWX:PPGN) from Draupnir Holding B.V. and others for CHF 1.5 billion.Samsung Biologics Co.,Ltd. (KOSE:A207940) entered into a transaction agreement to acquire PolyPeptide Group AG (SWX:PPGN) from Draupnir Holding B.V. and others for CHF 1.5 billion on July 17, 2026. Under the terms of the agreement, Samsung Biologics agreed to make an all-cash public tender offer to acquire all publicly held registered shares of PolyPeptide for CHF 44.31 in cash per share. The Offer values PolyPeptide's equity at approximately CHF 1.46 billion. The transaction aims to provide PolyPeptide with the resources, investment capacity and strategic platform to pursue the next phase of its growth and innovation. Alongside Samsung Biologics’ global manufacturing scale and track record of operational excellence, PolyPeptide will also benefit from an aligned customer footprint. Draupnir Holding B.V. owning a stake of approximately 56.3% stake has been in support of the strategic review process and has committed to tender all of its shares into the offer. Once the offer has been successfully completed, Samsung Biologics intends to pursue a squeeze-out of any remaining minority shares and to delist PolyPeptide from the SIX Swiss Exchange. Upon completion, PolyPeptide will operate as a wholly owned subsidiary of Samsung Biologics. The transaction is subject to approval by the shareholders of PolyPeptide Group AG, minimum acceptance threshold of 66?%, applicable regulatory approvals, and other conditions. The Board of Directors of PolyPeptide Group AG formed a special committee for the transaction. The deal has been unanimously approved by the special committee of board of directors of PolyPeptide Group AG and recommends that PolyPeptide shareholders accept the tender offer. The tender offer is expected to be launched by the end of August 2026 by publication of the formal offer prospectus and will remain open for a minimum of twenty trading days on the SIX Swiss Exchange. The transaction is expected to be completed towards the end of 2026. JP Morgan Korea acted as exclusive financial advisor to Samsung Biologics Co.,Ltd. Ernst & Young, Korea acted as accountant to Samsung Biologics Co.,Ltd. O'Melveny & Myers LLP, Seoul office acted as legal advisor to Samsung Biologics Co.,Ltd. Schellenberg Wittmer acted as legal advisor to Samsung Biologics Co.,Ltd. IFBC AG acted as fairness opinion provider to PolyPeptide Group AG. Morgan Stanley & Co. International plc acted as exclusive financial advisor to PolyPeptide Group AG. Homburger AG acted as legal advisor to PolyPeptide Group AG.
New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Buy Or Sell Opportunity • Mar 31Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 5.3% to CHF27.31. The fair value is estimated to be CHF22.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company became loss making.
お知らせ • Mar 18PolyPeptide Group AG, Annual General Meeting, Apr 08, 2026PolyPeptide Group AG, Annual General Meeting, Apr 08, 2026, at 16:00 W. Europe Standard Time.
Reported Earnings • Mar 14Full year 2025 earnings released: €0.64 loss per share (vs €0.59 loss in FY 2024)Full year 2025 results: €0.64 loss per share (further deteriorated from €0.59 loss in FY 2024). Revenue: €391.9m (up 16% from FY 2024). Net loss: €21.2m (loss widened 8.2% from FY 2024). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
Buy Or Sell Opportunity • Jan 19Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to CHF29.73. The fair value is estimated to be CHF24.51, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.7% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 18% in a year. Earnings are forecast to grow by 92% in the next year.
お知らせ • Dec 05+ 1 more updatePolyPeptide Group AG to Report Fiscal Year 2026 Results on Mar 09, 2027PolyPeptide Group AG announced that they will report fiscal year 2026 results on Mar 09, 2027
お知らせ • Sep 23PolyPeptide Group AG Achieves Significant Milestone in Malmo Expansion ProjectPolyPeptide Group AG announced the successful delivery and installation of pre-built modules at its Malmo, Sweden facility. This marks a key milestone in the company's modular expansion project at the site, which aims to double its solid-phase peptide synthesis (SPPS) capacity. The expansion, first announced in January 2025, is a central component of PolyPeptide's mid-term strategy to meet rising global demand for peptide production. The EUR 100 million metabolic program investment was largely funded by a large pharmaceutical partner and will create around 100 permanent new positions. It is anticipated that the expansion will be significantly faster than previous engineering projects due to the modular construction approach. Following installation, the modules will now undergo mechanical completion and automation, followed by qualification and commissioning. Key Project Highlights: Accelerated timeline: The Malmo capacity expansion is on track to be faster than previous engineering expansions due to the modular approach. Strategic partnership: The EUR 100 million investment was largely funded by a largest pharmaceutical player. Modular construction: Pre-built manufacturing modules installed with proprietary manufacturing systems, delivered and installed on-site. Operational continuity: Existing manufacturing operations remain uninterrupted. Advanced technology: Integrated engineering, automation, and process control. Quality assurance: All modules built to meet stringent pharmaceutical GMP standards. The additional capacity will primarily support one of PolyPeptide's large commercial agreements, contributing to its long-term growth initiatives and capital deployment strategy. As communicated in its mid-term outlook, the company expects over the mid-term horizon and on average, capital expenditures of 15-20% of revenue to ensure capacity beyond 2028.
Reported Earnings • Aug 14First half 2025 earnings released: €0.80 loss per share (vs €0.35 loss in 1H 2024)First half 2025 results: €0.80 loss per share (further deteriorated from €0.35 loss in 1H 2024). Revenue: €167.1m (up 24% from 1H 2024). Net loss: €26.5m (loss widened 133% from 1H 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
New Risk • Aug 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Apr 11Polypeptide Group Ag Appoints Jo Lecouilliard as Independent DirectorPolyPeptide Group AG announced the appointment of Jo LeCouilliard as Independent Director.
Buy Or Sell Opportunity • Apr 07Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 52% to CHF14.27. The fair value is estimated to be CHF17.84, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years. Meanwhile, the company became loss making.
New Risk • Mar 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (7.8% average weekly change).
Buy Or Sell Opportunity • Jan 23Now 24% overvaluedOver the last 90 days, the stock has fallen 4.9% to CHF27.25. The fair value is estimated to be CHF21.98, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 18% in a year. Earnings are forecast to grow by 95% in the next year.
New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Buy Or Sell Opportunity • Dec 16Now 29% overvaluedOver the last 90 days, the stock has fallen 8.5% to CHF29.70. The fair value is estimated to be CHF23.11, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Nov 25Now 21% overvaluedOver the last 90 days, the stock has fallen 19% to CHF27.70. The fair value is estimated to be CHF22.88, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Meanwhile, the company became loss making.
New Risk • Aug 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Buy Or Sell Opportunity • Apr 02Now 23% undervaluedOver the last 90 days, the stock has risen 63% to CHF28.55. The fair value is estimated to be CHF36.86, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 8.8% in a year. Earnings are forecast to grow by 77% in the next year.
Reported Earnings • Mar 14Full year 2023 earnings released: €1.56 loss per share (vs €0.23 profit in FY 2022)Full year 2023 results: €1.56 loss per share (down from €0.23 profit in FY 2022). Revenue: €324.9m (up 16% from FY 2022). Net loss: €51.4m (down €59.2m from profit in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom.
お知らせ • Dec 19PolyPeptide Group AG, Annual General Meeting, Apr 09, 2025PolyPeptide Group AG, Annual General Meeting, Apr 09, 2025.
お知らせ • Dec 17+ 1 more updatePolyPeptide Group AG to Report First Half, 2025 Results on Aug 12, 2025PolyPeptide Group AG announced that they will report first half, 2025 results on Aug 12, 2025
Reported Earnings • Aug 19First half 2023 earnings released: €1.04 loss per share (vs €0.31 profit in 1H 2022)First half 2023 results: €1.04 loss per share (down from €0.31 profit in 1H 2022). Revenue: €131.8m (down 1.4% from 1H 2022). Net loss: €34.3m (down 434% from profit in 1H 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in the United Kingdom.
Board Change • Jul 26High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. Non-Executive Director Erik Schropp is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Feb 08+ 3 more updatesPolyPeptide Group AG to Report First Half, 2024 Results on Aug 13, 2024PolyPeptide Group AG announced that they will report first half, 2024 results on Aug 13, 2024